ACT Style Guidelines
When ever possible is it best to design pages for ACTMagazine.com using as much HTML styled text as possible. This page provides guidance on designing content for the primary (center) column. Below you will also find examples of HTML styled text as it will appear in the primary column of ACTmagazine.com.
Content for the primary column should be designed to fit a maximun column width of 620 pixels.
The color palette for ACTMagazine.com is as follows:
red color: #8E0006 RED COLOR span class="red"
red link hover color: #B8000F RED COLOR
dark gray color: #333 DARK GRAY span class="darkgray"
light gray color: #333 LIGHT GRAY span class="lightgray"
yellow color: #FFFFCC YELLOW span class="yellow"
HTML styling on ACTMagazine.com:
[P] Tri tc grupo triliono la?longe, ig tiea seksa ies. Er ism okej multa ablativa, u a? peta kvanta. Veo peti ikso ol, ien danki tamen et. Ebl oj brosi pentekosto profitanto. Be mil dato maksimume, o peta estro nen. Ree si titolo kapabl vortludo. Adjektiva dikfingro kunmeta?o ik sia, armo s'joro log in. Veka krome lanta via ac. Nk elen hoketo nominativa cis, mal samo sekso dekuma da, so devi komplika int. To pro samo e?o kernovorto, far spite kasedo ekkria ut. Super turpa emfazado jen as, hago lasta iufoje io tet. Mono onjo gardi ha sia, poa centi refleksiva ut. Ia deci usono anta?eniri cit, pri alial proto frakcistreko am. Altlernejo prirespondi unu nf, iam unuj da?rigi ig. Dum rilata dekuma ut, emfazo kazablanko beda?rinde ing id, geto minimume centimetro muo um. Mal jo apud konsonanto, sur kapabl dekuma okulvitroj if. Bisi ikso sanskrito men if, hago ologi la nea. Unt ie iama pluso. To poa estro priskribo, sed bv finnlando multiplikite, vendo kvanta postesigno tio re. Cia ju proto minca, at iam na? haltostreko demandovorto. Oj mini jesa makro hot. Piko pago ekstera?o far fo, sat giga bat'o priskribo gh, ge ebl sude.
[link style in P tag] Be mil dato maksimume o peta estro nen. Ree si titolo kapabl vortludo.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.